Trials / Completed
CompletedNCT04683029
A Study of Guselkumab in Participants With Systemic Sclerosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab Dose 1 | Guselkumab Dose 1 will be administered intravenously. |
| DRUG | Guselkumab Dose 2 | Guselkumab Dose 2 will be administered subcutaneously. |
| DRUG | Placebo | Placebo will be administered intravenously or subcutaneously. |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2023-05-17
- Completion
- 2024-07-09
- First posted
- 2020-12-24
- Last updated
- 2025-07-23
- Results posted
- 2024-10-09
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04683029. Inclusion in this directory is not an endorsement.